Resorcinol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Resorcinol: From an Unrecorded Original Indication to Acne Keloid
One-Sentence Summary
Resorcinol is registered in South Africa as a component of the Anugesic suppository, but the record does not state its approved indication. The TxGNN model predicts it may be useful for acne keloid (acne keloidalis), with a score of 99.83%. There are 0 clinical trials and 0 publications supporting this prediction, so it is a model-only hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration record |
| Predicted New Indication | Acne keloid |
| TxGNN Prediction Score | 99.83% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Note on the registration data: The Evidence Pack lists its regulatory inputs as TFDA and DrugBank, not SAHPRA. The licence number “E512” also does not follow the SAHPRA registration format. The market status and registration count above should be confirmed against the SAHPRA register before anyone relies on them.
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available, and the registration record gives no approved indication. The mechanistic reasoning below is therefore general pharmacological knowledge, not something taken from the Evidence Pack.
Topical resorcinol is generally described as a keratolytic and antiseptic used in acne and seborrhoeic skin conditions. That could plausibly relate to the follicular inflammation seen in acne keloidalis. It would not address the fibrotic scarring that defines the condition, so this link is a hypothesis only.
The registered product, Anugesic, is a suppository. That is a rectal route, not the topical route implied by the dermatological rationale. Route compatibility between the registered product and the predicted indication has not been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| E512 | Anugesic | Suppository | Not stated in the record |
Essential Medicines List (EML) status is not available in the Evidence Pack.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
The Evidence Pack contains no warnings, contraindications, or interaction data for this drug. The only safety point in the pack comes from the rationale for a different prediction, neonatal dermatomyositis. It notes that resorcinol absorption in neonates carries known toxicity risks, such as methemoglobinaemia. Any future work should treat neonates and infants with caution.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no trials, no publications, and no recorded mechanism. The only registered product is a suppository, which does not match the topical use the hypothesis assumes. All nine other predicted indications in the pack (rank 2 to 10) are also rated Hold, and none has supporting evidence.
To proceed, the following is needed:
- The SAHPRA package insert (warnings, contraindications, approved indication) for Anugesic, which is currently a blocking gap
- Confirmation that the registration record is a genuine SAHPRA entry
- Mechanism of action data, for example from DrugBank
- A literature and trial search specific to resorcinol in acne keloidalis
- An assessment of whether a topical resorcinol product is available in South Africa, since the current registration is a suppository
- A safety review of systemic absorption and methemoglobinaemia risk
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.